KOD · Kodiak Sciences Inc.

Kodiak Sciences’ Q1 2026 financial results reflect continued investment in late-stage clinical execution, with R&D expenses increasing 11% year-over-year to $48.5 million—driven explicitly by advancing the PEAK/PINNACLE (MESI) and DAYBREAK (wet AMD) studies. Net loss narrowed slightly to $58.2 million ($0.94/share) from $57.5 million ($1.09/share) in Q1 2025, aided by a $4.2 million decline in G&A expenses (to $11.2 million), partially offset by higher clinical spend and lower stock-based compensation expense ($12.2M vs. $15.9M). Management emphasized that the positive GLOW2 data—demonstrating robust efficacy and safety in diabetic retinopathy—cements Zenkuda’s BLA-readiness across multiple indications, including DR, RVO, and wet AMD. The company highlighted its strategic pivot toward regulatory submission and near-term catalysts: DAYBREAK topline data in September 2026 (evaluating both Zenkuda and KSI-501 against aflibercept) and PEAK topline results in Q4 2026 (KSI-101 in MESI). With $169.5 million in cash as of March 31, 2026, Kodiak affirmed runway into 2027—sufficient to support these pivotal readouts and the planned first multi-indication BLA submission. No forward financial guidance was provided; however, the press release underscored clinical durability, real-world applicability (e.g., efficacy independent of GLP-1 use), and differentiated mechanisms (e.g., KSI-501’s dual IL-6/VEGF inhibition) as core value drivers.